Claims for Patent: 9,186,336

Summary for Patent: 9,186,336

Title:	Methods of treating vascular lesions
Abstract:	Described are methods of treating virus-associated lesions using administration of an anti-angiogenic compound, or a combination of angiolytic or ablative therapy and administration of an anti-angiogenic compound.
Inventor(s):	Zeitels; Steven M. (Newton, MA)
Assignee:	The General Hospital Corporation (Boston, MA)
Application Number:	13/147,844
Patent Claims:	1. A method of treating laryngeal recurrent respiratory papillomatosis (RRP) and maintaining or improving mucosal pliability in the larynx in a human subject, the method comprising locally administering to a phonatory mucosal surface in the larynx of the subject in need thereof an anti-VEGF antibody that binds to human VEGF-A in an amount effective to inhibit RRP and to maintain or improve mucosal pliability in the larynx. 2. The method of claim 1, further comprising a cytoreductive treatment sufficient to debulk a lesion caused by the RRP. 3. The method of claim 1, wherein the anti-VEGF antibody is bevacizumab. 4. The method of claim 1, wherein the local administration to the mucosal surface of the larynx is direct transoral injection into, or topical application onto, a vocal fold, or into or onto mucosal surfaces in the larynx adjacent to the vocal fold. 5. The method of claim 4, wherein the anti-VEGF antibody is administered locally using a controlled-release formulation. 6. The method of claim 2, wherein the cytoreductive treatment is provided by a laser selected from the group consisting of a CO2 laser, an Nd:YAG laser, a Thulium laser; an Er,Cr:YSGG laser; a 532-nm pulsed potassium titanyl phosphate (KTP) laser; or a 585-nm pulsed dye laser (PDL). 7. The method of claim 2, wherein the cytoreductive treatment is provided by cold instruments. 8. The method of claim 2, wherein the cytoreductive treatment is an ablative tissue treatment. 9. The method of claim 1, further comprising administering one or more additional doses of the anti-VEGF antibody at subsequent times. 10. The method of claim 1, wherein the anti-VEGF antibody is ranibizumab. 11. A method of maintaining or improving phonatory mucosal pliability in the larynx in a human subject suffering from a lesion caused by a human papilloma virus (HPV), the method comprising locally administering to a phonatory mucosal surface in the larynx an anti-VEGF antibody that binds to human VEGF in an amount effective to maintain or improve phonatory mucosal pliability in the larynx. 12. The method of claim 11, further comprising a cytoreductive treatment sufficient to debulk the lesion. 13. The method of claim 11, wherein the anti-VEGF antibody is bevacizumab. 14. The method of claim 11, wherein the local administration to the mucosal surface of the larynx is direct transoral injection into, or topical application onto, a vocal fold, or into or onto mucosal surfaces adjacent to the vocal fold. 15. The method of claim 11, wherein the anti-VEGF antibody is administered locally using a controlled-release formulation. 16. The method of claim 12, wherein the cytoreductive treatment is provided by cold instruments. 17. The method of claim 12, wherein the cytoreductive treatment is an ablative tissue treatment. 18. The method of claim 1, further comprising administering one or more additional doses of the anti-VEGF antibody at subsequent times. 19. The method of claim 12, wherein the cytoreductive treatment is provided by a laser selected from the group consisting of a CO2 laser, an Nd:YAG laser, a Thulium laser; an Er,Cr:YSGG laser; a 532-nm pulsed potassium titanyl phosphate (KTP) laser; or a 585-nm pulsed dye laser (PDL). 20. The method of claim 19, wherein the cytoreductive treatment is provided by a 532-nm pulsed potassium titanyl phosphate (KTP) laser. 21. The method of claim 2, wherein the cytoreductive treatment is provided by a 532-nm pulsed potassium titanyl phosphate (KTP) laser. 22. The method of claim 1, wherein the mucosal surface is on at least one of the patient's vocal folds and the anti-VEGF antibody is injected into phonatory mucosa of the vocal fold. 23. The method of claim 22, wherein the anti-VEGF antibody is injected into the superficial lamina propria of the vocal fold. 24. The method of claim 11, wherein the mucosal surface is on at least one of the patient's vocal folds and the anti-VEGF antibody is injected into phonatory mucosa of the vocal fold. 25. The method of claim 24, wherein the anti-VEGF antibody is injected into the superficial lamina propria of the vocal fold. 26. The method of claim 4, wherein the direct transoral injection into the vocal fold comprises injection into the superficial lamina propria. 27. The method of claim 14, wherein the direct transoral injection into the vocal fold comprises injection into the superficial lamina propria. 28. The method of claim 1, wherein the method reduces recurrence of the RRP and improves voice quality of the subject. 29. The method of claim 11, wherein the method reduces recurrence of lesions caused by HPV and improves voice quality of the subject.

Details for Patent 9,186,336

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2029-02-06
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2029-02-06
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2029-02-06
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2029-02-06